astrazeneca-us.com Report : Visit Site

Technical data of the astrazeneca-us.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host astrazeneca-us.com. Currently, hosted in United Kingdom and its service provider is Digitaslbi Limited .

the related websites

jobs.newscientist.com clinicaltrialdoctors.com ukmi.nhs.uk jobisjob.co.uk astrazeneca-annualreports.com dk.com beneteau.com easynet.com cimaglobal.com destinationimagination.org iaeste.org teamxlink.co.uk peaceoneday.org bbc.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

skip to content skip to navigation cookie policy this website uses cookies to help us give you the best experience when you visit. by using this website you consent to our use of these cookies. find out more about how we use cookies and how to manage them by reading our cookie notice. close search menu search search search close astrazeneca in the united states astrazeneca in the us contact us sustainability sustainability patient programs improving access to care health and science innovation employee volunteerism and giving request support astrazeneca healthcare foundation responsible business corporate transparency medicines astrazeneca medications affordability astrazeneca direct product counterfeiting medical information for healthcare providers careers careers military careers media media blog more hide astrazeneca websites global site welcome to astrazeneca united states beginning its journey in 1953, astrazeneca became one of the first pharmaceutical companies operating in the united states quick links astrazeneca in the us az&you blog medicines media careers contact 4 big ways employees gave back during “power of us week” power of us week is a special time we set aside to volunteer with our colleagues all across the country. see our blog post celebrating inclusion and diversity during lgbtqa pride month we’re focused on fostering a vibrant work culture, where everyone is respected and has a sense of belonging. see our blog post latest news from astrazeneca united states astrazeneca to share latest data from an industry-leading portfolio that aims to advance clinical understanding of diabetes and cv risk management at ada 2018 key data evaluating the efficacy and safety of dapagliflozin in combination with other type 2 diabetes therapies head-to-head vs. insulin or sulfonylurea latest data from the depict clinical program evaluating dapagliflozin to address an unmet need for oral therapy in adult patients with type 1 diabetes debut of pre-clinical and clinical data for medi0382 in type 2 diabetes, a potential first-in-class oxyntomodulin-like peptide faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (pfs) second approval in three months expands treatment options for women with hr+, her2- advanced breast cancer 19 june 2018 lynparza® (olaparib) in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer lynparza is the first and only parp inhibitor to demonstrate activity in combination with standard-of-care treatment in prostate cancer astrazeneca and merck presented results of study 08 at the 2018 asco annual meeting with simultaneous publication in the lancet oncology faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (pfs) second approval in three months expands treatment options for women with hr+, her2- advanced breast cancer 4 june 2018 @astrazenecaus on twitter astrazenecaus @astrazenecaus we are days away from the start of #2018ada! who is attending this year’s conference in orlando? reply retweet 0 favorite 0 jun 20 astrazenecaus @astrazenecaus we built, we cleaned, we assembled, we taught, we connected, we supported. all of this and more during our annual p… https://t.co/fcv4k1dxrf reply retweet 0 favorite 1 jun 20 astrazenecaus @astrazenecaus looking forward to #2018ada where we will feature nearly 50 abstracts advancing the science of #diabetes. visit our… https://t.co/9ulowxw18i reply retweet 0 favorite 0 jun 20 follow astrazenecaus moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukemia presented at the 2018 asco meeting study meets the primary endpoint of durable complete response majority of patients who had a complete response had no evidence of any remaining detectable cancer cells phase iii clinical trial results served as basis for recent us fda regulatory submission faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (pfs) second approval in three months expands treatment options for women with hr+, her2- advanced breast cancer 2 june 2018 imfinzi® (durvalumab) significantly improves overall survival in the phase iii pacific trial for unresectable stage iii non-small cell lung cancer imfinzi met the second primary endpoint of overall survival which was both statistically significant and clinically meaningful at a planned interim analysis faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (pfs) second approval in three months expands treatment options for women with hr+, her2- advanced breast cancer 25 may 2018 latest az&you blog articles 5 ways we’re fighting cancer in the us 29 may 2018 what we’re watching during asco 2018 29 may 2018 reducing the burden of diabetes: 3 takeaways from the ada’s recent report 21 may 2018 patient advocacy leader shares advice for people living with bladder cancer 3 may 2018 making some sense of lung cancer 18 april 2018 lung cancer treatment today: earlier and more precise 13 april 2018 bob harper on connecting with fellow heart attack survivors 6 april 2018 meet the survivors have heart essay contest winners 1 march 2018 here’s what metastatic breast cancer patients want you to know 22 february 2018 a year’s worth of giving: our 2017 power of us impact 22 january 2018 community programs help improve heart health and share lessons learned 18 january 2018 moving forward as a heart attack survivor 16 january 2018 employees give back to those affected by natural disasters in 2017 19 december 2017 stories of hope from people with lymphoma 4 december 2017 advancing stem through the health & science innovation challenge 28 november 2017 more than a tagline: delivering value to patients 14 november 2017 understanding if your asthma is severe 20 november 2017 from ‘scanxiety’ to living life fully: robert’s stage iii lung cancer story 10 november 2017 why we’re talking about cvmd 9 november 2017 a mother’s strategy to protect against rsv 4 october 2017 living with metastatic breast cancer: swimmer raises awareness and research funding 2 october 2017 5 important things to know about lung cancer 7 september 2017 expanding treatment options to address unmet need in blood cancer 5 september 2017 astrazeneca supports hurricane harvey relief efforts 30 august 2017 employees donate their time to support communities during power of us week 20 june 2017 personalizing lung cancer: why testing matters 3 june 2017 making science understandable and accessible for cancer patients 30 may 2017 how the chest foundation is addressing the needs of severe asthma patients 19 may 2017 more than 4.5 million patients assisted over ten years 15 may 2017 knowing your options when facing advanced bladder cancer 1 may 2017 advancing science and accelerating innovation in the biohealth capital region 27 april 2017 supporting patients and communities: our 2016 corporate responsibility at a glance 21 april 2017 a new approach to reducing lung cancer deaths and extending lives 23 march 2017 the power of us: employees’ community impact in 2016 6 january 2017 our favorites from 2016 – highlights of the az&you blog throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. from the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over. 20 december 2016 stigma, genetics and hope: 11 years with lung cancer in 2005, melissa crouse was diagnosed with lung cancer and given three to five years to live. eleven years later, melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. melissa shares her perspective on living with lung cancer, understanding

URL analysis for astrazeneca-us.com

https://www.astrazeneca-us.com///sustainability/employee-volunteerism-giving.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2018/meet-the-survivors-have-heart-essay-contest-winners-03012018.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2016/personalized-healthcare-what-it-means-and-why-it-matters-11282016.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2016/perspectives-on-cardiovascular-disease-a-multi-faceted-03312016.html
https://www.astrazeneca-us.com//#navigation
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2017/employees-give-back-to-those-affected-by-natural-disasters-in-2017-12192017.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2016/navigating-cancer-clinical-trials-where-to-start-10182016.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2017/knowing-your-options-when-facing-advanced-bladder-cancer-05012017.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2017/5-important-things-to-know-about-lung-cancer-09072017.html
https://www.astrazeneca-us.com///medicines/product-counterfeiting.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2018/patient-advocacy-leader-shares-advice-for-people-living-with-bladder-cancer-05032018.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2016/new-resource-offers-24-7-support-for-those-with-mental-illness-092620161.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2016/what-does-the-new-cancerlinq-discovery-initiative-mean-for-the-future-of-patient-care-11302016.html
https://www.astrazeneca-us.com///media/astrazeneca-us-blog/2017/employees-donate-their-time-to-support-communities-during-power-of-us-week-06202017.html

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: ASTRAZENECA-US.COM
Registry Domain ID: 4796331_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corporatedomains.com
Registrar URL: http://www.cscglobal.com/global/web/csc/digital-brand-services.html
Updated Date: 2016-12-05T07:10:06Z
Creation Date: 1998-12-10T05:00:00Z
Registry Expiry Date: 2017-12-09T05:00:00Z
Registrar: CSC Corporate Domains, Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 8887802723
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS1.CSCDNS.NET
Name Server: DNS2.CSCDNS.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-10-04T13:09:35Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR CSC Corporate Domains, Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =astrazeneca-us.com

  PORT 43

  TYPE domain

DOMAIN

  NAME astrazeneca-us.com

  CHANGED 2016-12-05

  CREATED 1998-12-10

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  DNS1.CSCDNS.NET 209.112.114.33

  DNS2.CSCDNS.NET 69.36.145.33

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .